Proteomic and phosphoproteomic analyses have also allowed to reveal mechanisms of activation of NEK2 and AURKA kinases in cancer (180), thus allowing the use of drugs targeting such kinases in six different cancer types within the Clinical Proteomic Tumor Analysis Consortium (CPTAC): Breast cancer, clear cell renal carcinoma, colon cancer, lung adenocarcinoma, ovarian cancer, and uterine corpus endometrial carcinoma. This evidence concerns the gene NEK2 and colonic neoplasm.